
Inhibikase Therapeutics Investor Relations Material
Latest events

Q2 2024
Inhibikase Therapeutics

Q1 2025
14 May, 2025

Q4 2024
27 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Inhibikase Therapeutics Inc
Access all reports
Inhibikase Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases and cancers. The company’s research primarily targets diseases related to protein misfolding, such as Parkinson's disease, by aiming to inhibit the malfunction of key cellular processes. Inhibikase Therapeutics develops therapeutics that aim to modify the progression of these diseases and improve patient outcomes. Its approach includes addressing both neurological and oncological conditions through small-molecule therapeutics. The company is headquartered in Atlanta, Georgia, and its shares are listed on the NASDAQ.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
IKT
Country
🇺🇸 United States